These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 17073711)

  • 41. Successful use of recombinant activated factor VII administered via automated bolus pump following emergency laparoscopic appendectomy in a patient with mild congenital FVII deficiency: Case report.
    Perkins H; Klaassen RJ
    Pediatr Blood Cancer; 2021 Aug; 68(8):e28974. PubMed ID: 33629793
    [No Abstract]   [Full Text] [Related]  

  • 42. Coagulation factor VII variants resistant to inhibitory antibodies.
    Branchini A; Baroni M; Pfeiffer C; Batorova A; Giansily-Blaizot M; Schved JF; Mariani G; Bernardi F; Pinotti M
    Thromb Haemost; 2014 Nov; 112(5):972-80. PubMed ID: 25104096
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety profile of recombinant factor VIIa.
    Roberts HR; Monroe DM; Hoffman M
    Semin Hematol; 2004 Jan; 41(1 Suppl 1):101-8. PubMed ID: 14872430
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Monitoring coagulation and the clinical effects of recombinant factor VIIa.
    Gabriel DA; Carr M; Roberts HR
    Semin Hematol; 2004 Jan; 41(1 Suppl 1):20-4. PubMed ID: 14872416
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prophylaxis of peripartum haemorrhage using recombinant factor VIIa (rfVIIa) in pregnant women with congenital factor VII deficiency: A case report and literature review.
    Loddo A; Cornacchia S; Cane FL; Barcellona D; Marongiu F; Melis GB; Angioni S; Paoletti AM; Neri M
    Eur J Obstet Gynecol Reprod Biol; 2019 Apr; 235():77-80. PubMed ID: 30831446
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recombinant FVIIa.
    Hedner U
    Vox Sang; 2004 Jul; 87 Suppl 2():25-8. PubMed ID: 15209873
    [No Abstract]   [Full Text] [Related]  

  • 47. Treatment of factor VII deficiency with recombinant factor VIIa.
    Bauer KA
    Haemostasis; 1996; 26 Suppl 1():155-8. PubMed ID: 8904192
    [TBL] [Abstract][Full Text] [Related]  

  • 48. To general haemostasis--the evidence-based route.
    Erhardtsen E
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():47-52. PubMed ID: 12214148
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A comparison between recombinant activated factor VII (Aryoseven) and Novoseven in patients with congenital factor VII deficiency.
    Faranoush M; Abolghasemi H; Toogeh G; Karimi M; Eshghi P; Managhchi M; Hoorfar H; Dehdezi BK; Mehrvar A; Khoeiny B; Kamyar K; Heshmat R; Baghaeipour MR; Mirbehbahani NB; Fayazfar R; Ahmadinejad M; Naderi M
    Clin Appl Thromb Hemost; 2015 Nov; 21(8):724-8. PubMed ID: 24651301
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Management of thrombocytopenic bleeding: is there a role for recombinant coagulation factor VIIa?
    Poon MC
    Curr Hematol Rep; 2003 Mar; 2(2):139-47. PubMed ID: 12901145
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A multicenter, observational study to evaluate hemostasis following recombinant activated FVII treatment in patients in Japan with congenital factor VII deficiency.
    Seita I; Kinai E
    Blood Coagul Fibrinolysis; 2023 Jul; 34(5):295-304. PubMed ID: 37395185
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The use of recombinant activated coagulation factor VII for spine surgery.
    Weiskopf RB
    Eur Spine J; 2004 Oct; 13 Suppl 1(Suppl 1):S83-8. PubMed ID: 15160317
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel applications of recombinant factor VIIa for the management of pediatric coagulopathic diseases.
    Mathew P; Winter SS; Frost JD; Hanrahan J; Schwartz M; Jones JE
    J Pediatr Hematol Oncol; 2003 Jun; 25(6):499-502. PubMed ID: 12794532
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [New therapeutic possibilities for uncontrolled bleeding].
    Mikos B; Kiss K; Bolyos A; Ormay C
    Orv Hetil; 2004 Jan; 145(3):111-7. PubMed ID: 15027332
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recombinant factor VIIa (Novoseven) restores deficient coagulation: experience from an ex vivo model.
    Galán AM; Tonda R; Altisent C; Maragall S; Ordinas A; Escolar G
    Semin Hematol; 2001 Oct; 38(4 Suppl 12):10-4. PubMed ID: 11735104
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mechanism of action, development and clinical experience of recombinant FVIIa.
    Hedner U
    J Biotechnol; 2006 Aug; 124(4):747-57. PubMed ID: 16697480
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review.
    Franchini M; Manzato F; Salvagno GL; Lippi G
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):589-93. PubMed ID: 17890943
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation.
    Gerotziafas GT; Chakroun T; Depasse F; Arzoglou P; Samama MM; Elalamy I
    Thromb Haemost; 2004 May; 91(5):977-85. PubMed ID: 15116259
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recombinant factor VIIa for refractory bleeding following orthotopic heart transplantation.
    Flynn JD; Pajoumand M; Camp PC; Jahania MS; Ramaiah C; Akers WS
    Ann Pharmacother; 2004 Oct; 38(10):1639-42. PubMed ID: 15340124
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel hemostatic agent: the potential role of recombinant activated factor VII (rFVIIa) in anesthetic practice.
    Murkin JM
    Can J Anaesth; 2002 Dec; 49(10):S21-6. PubMed ID: 12546007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.